Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's Q2 performance exceeded expectations, with significant improvements in net profit and revenue compared to the previous quarter, indicating a positive trend for the new materials platform in the future [6] - The company is focusing on high-value-added materials, with a notable recovery in its MP business and ongoing development in semiconductor materials, high-performance polymers, and new energy materials [6] Financial Data and Earnings Forecast - Total revenue for 2025 is projected to be 3,924 million yuan, with a year-on-year growth rate of 6.3% [5] - The net profit attributable to the parent company is expected to reach 459 million yuan in 2025, reflecting an 86.2% increase year-on-year [5] - The company achieved a gross margin of 39.9% and a net margin of 16.02% in Q2 2025, showing improvements in profitability [6] - R&D expenses for Q2 2025 were 115 million yuan, representing 11.45% of revenue, indicating a strong commitment to innovation [6] Business Segment Performance - The functional materials segment reported revenue of 1,469 million yuan in H1 2025, down 10% year-on-year, while the pharmaceutical materials segment saw a 21% increase in revenue to 376 million yuan [6] - The OLED terminal materials and PI materials are experiencing significant growth, while the molecular sieve business is under pressure due to weak downstream demand [6] - The company is actively developing new products in semiconductor materials and has initiated projects to expand production capacity for photolithography materials and polyimide materials [6]